CU20220023A7 - Derivados de 2-azaspiro[3,4]octano como agonistas de m4 - Google Patents

Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Info

Publication number
CU20220023A7
CU20220023A7 CU2022000023A CU20220023A CU20220023A7 CU 20220023 A7 CU20220023 A7 CU 20220023A7 CU 2022000023 A CU2022000023 A CU 2022000023A CU 20220023 A CU20220023 A CU 20220023A CU 20220023 A7 CU20220023 A7 CU 20220023A7
Authority
CU
Cuba
Prior art keywords
agonists
azaspiro
octane derivatives
formula
octane
Prior art date
Application number
CU2022000023A
Other languages
English (en)
Inventor
Amy Calhoun
Xin Chen
Kevin Matthew Gardinier
Edward Charles Hall
Keith Jendza
Nancy Labbe-Giguere
James Neef
Daniel Steven Palacios
Ming Qian
Michael David Shultz
Christopher G Thomson
Kate Yaping Wang
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20220023A7 publication Critical patent/CU20220023A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

<p>En la presente se proporcionan compuestos de acuerdo con la Fórmula (I)</p> <p> </p> <p>ESPACIO PARA FÓRMULA</p> <p> </p> <p>o una sal farmacéuticamente aceptable de los mismos, en donde R1, R2, R3, R5, y R7 se definen en la presente. También se proporcionan en la presente composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.</p>
CU2022000023A 2019-10-09 2020-10-07 Derivados de 2-azaspiro[3,4]octano como agonistas de m4 CU20220023A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912980P 2019-10-09 2019-10-09
PCT/IB2020/059430 WO2021070090A1 (en) 2019-10-09 2020-10-07 2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
CU20220023A7 true CU20220023A7 (es) 2022-11-07

Family

ID=72944205

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000023A CU20220023A7 (es) 2019-10-09 2020-10-07 Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Country Status (24)

Country Link
US (2) US11548865B2 (es)
EP (1) EP4041389A1 (es)
JP (1) JP7349570B2 (es)
KR (1) KR20220079921A (es)
CN (1) CN114555592B (es)
AR (1) AR120170A1 (es)
AU (1) AU2020361735B2 (es)
CA (1) CA3156320A1 (es)
CL (1) CL2022000893A1 (es)
CO (1) CO2022004341A2 (es)
CR (1) CR20220141A (es)
CU (1) CU20220023A7 (es)
DO (1) DOP2022000073A (es)
EC (1) ECSP22027287A (es)
IL (1) IL291316A (es)
JO (1) JOP20220082A1 (es)
MX (1) MX2022004213A (es)
PE (1) PE20221453A1 (es)
PH (1) PH12022550859A1 (es)
PY (1) PY2061937A (es)
TW (1) TW202128649A (es)
UY (1) UY38906A (es)
WO (1) WO2021070090A1 (es)
ZA (1) ZA202202912B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555592B (zh) * 2019-10-09 2024-09-06 诺华股份有限公司 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物
EP4587432A1 (en) * 2022-09-16 2025-07-23 Cerevel Therapeutics, LLC M4 activators/modulators and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
EP2064187A2 (en) 2006-08-25 2009-06-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
UY31672A1 (es) 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
CA2750777C (en) 2009-01-26 2018-04-03 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
CN103443105A (zh) 2011-02-18 2013-12-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺
WO2013013308A1 (en) 2011-07-27 2013-01-31 Beta Pharma Canada Inc. Spirocyclic molecules as protein kinase inhibitors
AU2013312896A1 (en) 2012-09-07 2015-02-26 Zoetis Services Llc Spirocyclic derivatives as antiparasitic agents
DK2897948T3 (en) * 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
EP3102568B1 (en) * 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
MX2017005484A (es) 2014-10-31 2017-10-20 Indivior Uk Ltd Compuestos antagonistas del receptor de dopamina d3.
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
KR102916887B1 (ko) 2016-06-10 2026-01-22 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20221454A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
CN114555592B (zh) * 2019-10-09 2024-09-06 诺华股份有限公司 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物

Also Published As

Publication number Publication date
AR120170A1 (es) 2022-02-02
DOP2022000073A (es) 2022-05-31
EP4041389A1 (en) 2022-08-17
AU2020361735B2 (en) 2024-04-18
JP7349570B2 (ja) 2023-09-22
TW202128649A (zh) 2021-08-01
PE20221453A1 (es) 2022-09-21
US11548865B2 (en) 2023-01-10
CN114555592B (zh) 2024-09-06
PH12022550859A1 (en) 2023-06-14
CA3156320A1 (en) 2021-04-15
WO2021070090A1 (en) 2021-04-15
US12122761B2 (en) 2024-10-22
CR20220141A (es) 2022-05-03
AU2020361735A1 (en) 2022-04-21
ECSP22027287A (es) 2022-12-30
CL2022000893A1 (es) 2023-01-20
CO2022004341A2 (es) 2022-04-29
ZA202202912B (en) 2023-04-26
IL291316A (en) 2022-05-01
CN114555592A (zh) 2022-05-27
US20230212139A1 (en) 2023-07-06
JOP20220082A1 (ar) 2022-04-05
UY38906A (es) 2021-05-31
MX2022004213A (es) 2022-05-03
PY2061937A (es) 2021-08-20
KR20220079921A (ko) 2022-06-14
JP2022552244A (ja) 2022-12-15
US20210107889A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
CO2020013564A2 (es) Compuestos heteroaril tetracíclicos
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
JOP20210005B1 (ar) عوامل تحلل مستقبلات الإستروجين الانتقائية
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MX2021011606A (es) Compuestos dirigidos a prmt5.
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
MX2022000598A (es) Preparacion de compuestos antibacterianos.
CL2020001817A1 (es) Moduladores del receptor c5a
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
MX2024012471A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR116080A1 (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso
AR124698A1 (es) Derivados tricíclicos útiles como inhibidores de parp7